Peter Emtage, vice president, immune mediated therapies, MedImmune, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.
These two molecules have different impacts on immune response, Emtage says. Preclinical studies have shown that synergies exist between the two molecules. This combination is being looked at in several indications to determine where these synergies exist.
Researchers saw some exciting and promising activity in this small study, Emtage says. The combination demonstrated an adequate level of tolerability to be studied further.
<<< View more from the 2014 ESMO Congress